Clinical trial
A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)
NCT07015983 is registered in ClinicalTrials.gov with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- July 14, 2025
- Completion date
- June 15, 2032
- Enrollment
- 89 (estimated)
- Sites
- 97
Conditions
As the registry lists them; a condition with its own page is linked.